Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Neurological Disorder Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 12.6% during the forecast period.
This report presents the market size and development trends by detailing the Neurological Disorder Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Neurological Disorder Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Neurological Disorder Drugs industry and will help you to build a panoramic view of the industrial development.
Neurological Disorder Drugs Market, By Type:
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Neurological Disorder Drugs Market, By Application:
Hospital
Clinic
Home
Some of the leading players are as follows:
Merck & Co
F Hoffmann-La Roche Ltd
AstraZeneca.
Teva Pharmaceutical Industries Ltd
Novartis AG.
Boehringer Ingelheim GmbH
Bayer AG
F. Hoffmann-La Roche Ltd.
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Neurological Disorder Drugs Market: Technology Type Analysis
-
4.1 Neurological Disorder Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Neurological Disorder Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Antipsychotic
4.3.2 Hypnotic & Sedative
4.3.3 Analgesics
4.3.4 Anticoagulants
4.3.5 Others
5 Neurological Disorder Drugs Market: Product Analysis
-
5.1 Neurological Disorder Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 Neurological Disorder Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Neurological Disorder Drugs Market: Application Analysis
-
6.1 Neurological Disorder Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 Neurological Disorder Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Home
7 Neurological Disorder Drugs Market: Regional Analysis
-
7.1 Neurological Disorder Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 Neurological Disorder Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Merck & Co
9.1.1 Merck & Co Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 F Hoffmann-La Roche Ltd
9.2.1 F Hoffmann-La Roche Ltd Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 AstraZeneca.
9.3.1 AstraZeneca. Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Teva Pharmaceutical Industries Ltd
9.4.1 Teva Pharmaceutical Industries Ltd Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Novartis AG.
9.5.1 Novartis AG. Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Boehringer Ingelheim GmbH
9.6.1 Boehringer Ingelheim GmbH Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Bayer AG
9.7.1 Bayer AG Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 F. Hoffmann-La Roche Ltd.
9.8.1 F. Hoffmann-La Roche Ltd. Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
The List of Tables and Figures (Totals 111 Figures and 144 Tables)
Figure Antipsychotic Neurological Disorder Drugs market, 2015 - 2026 (USD Million)
Figure Hypnotic & Sedative Neurological Disorder Drugs market, 2015 - 2026 (USD Million)
Figure Analgesics Neurological Disorder Drugs market, 2015 - 2026 (USD Million)
Figure Anticoagulants Neurological Disorder Drugs market, 2015 - 2026 (USD Million)
Figure Others Neurological Disorder Drugs market, 2015 - 2026 (USD Million)
Figure Hospital market, 2015 - 2026 (USD Million)
Figure Clinic market, 2015 - 2026 (USD Million)
Figure Home market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Neurological Disorder Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe Neurological Disorder Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Neurological Disorder Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Neurological Disorder Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA Neurological Disorder Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Neurological Disorder Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Neurological Disorder Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Neurological Disorder Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Merck & Co Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table F Hoffmann-La Roche Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Teva Pharmaceutical Industries Ltd Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis AG. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Boehringer Ingelheim GmbH Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer AG Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table F. Hoffmann-La Roche Ltd. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
